Showing posts with label endometrial cancer. Show all posts
Showing posts with label endometrial cancer. Show all posts

Thursday, June 4, 2026

Review of #ASCO26 - Gyn Cancer Oral Abstract Sessions, May 29th sessions

I did not attend ASCO in person this year but rather I watched sessions live.  When not available live I watched session On Demand the next day.  I continued the tradition I started when I attended meetings in person.  I posted on X (Twitter) summarizing and sharing slides from the presentations. 

The Oral Abstract Session for Gynecologic Cancers was held on Friday, May 29th. My focus what on ovarian cancer treatment research. ( Although there is one endometrial trial in this post) 

 Endometrial Cancer: Ruby Trial Dostarlimab + Chemo Abs 5501

 Ovarian Cancer  NRG GY018  Abs 5502

Ovarian Cancer ROSELLA trial  Abs 5503

 Late Breaking Abstract CHIPRO  LBA 5504

 Ovarian Cancer CHRONO Abs 5505

 

Distillation of these studies : 

Ovarian Cancer Phase 2 MIRV trial Abs 5506

 

I'll post over the next few days other ASCO sessions including - Rapid Oral Abstracts, Surgery vs NACT, and the Poster Session. 

Dee

Every Day is a Blessing!  

Posted by at No comments:
Labels: , , , , , , , , ,

Thursday, June 6, 2024

Sunday at #ASCO24 Oral Abstracts and Rare Gyn Cancers

My meeting days all started with picking up a bite to eat in the Patient Lounge. The lounge was a great place to meet up with other advocates from around the world, relax is comfy chairs  and pick up a bite to eat at breakfast or lunch. 

Sunday started with the Gyn Cancer Oral Abstract Session followed by an afternoon of meeting with clinicians I am working with as well as learning about Patient Story .

Clear Cell OC

 Recurrent OC no additional benefits from adding Atezolizumab

 Endometrial Cancer 

Pharma support of trials 

When Bad News Comes Through the Portal ... Education Session

Exploring the Uncommon: What's New in Rare Gyn Cancers  - Low grade serous , Melanoma of the gyn tract and neuroendocrine carcinomas of the cervix

Obesity and Endometrial Cancer

Cervical Cancer

Metastatic disease clinical trials 

 Tomorrow I'll review a few of the posters as well as a round-up of the connections I made. 


Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , ,

Monday, March 18, 2024

2024 SGO Annual Meeting Saturday March 16th Session Review


 

I virtually attended five sessions on day one of the SGO Annual Meeting -  the Opening Ceremony, News We Can All use (Plenary), Moving the Needle (Plenary), Science to Drive Purpose(Plenary)  and Together We Tackle Cancer Rapid Fire Poster Sessions. (Saturday March 16,2024.)

Please be patient while reading this post since it may take some time for all the X posts and photos to download. 

I'm going to start this post by giving a shout out to the patients and advocates involved in presenting on Saturday.  Check out Susan, Linda, Shawn and Jennifer!

Here are just a few of the 60 tweets & retweets I shared during the Saturday meeting.  

Endometrial Cancer

Ovarian Cancer 

HER -2 Expressing Tumors 

Cervical Cancer

Ovarian Cancer 

Endometrial Cancer

Ovarian Cancer

 Recurrent Endometrial, Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Ovarian Cancer

Endometrial Cancer

Together We Tackle Cancer Session:

I'll keep you updated on what I learned on Sunday and Monday in the next few days.   


Dee 

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , ,

Wednesday, June 7, 2023

ASCO 2023 Day 2: Opening Session, GTD Panel , Gyn Cancer Oral Abstract session

Note: Due to the number of Tweets embedded in this post the page may take some time to load.

Saturday was a busy day at #ASCO23. For me it included live sessions, on-demand sessions and two meetings. 

 Opening Session

 

 

 

The session finished with a chat with the Surgeon General, Dr Vivak Murphy who discussed a range of topics. 


 Case-based Panel - GTD

This session which talked about a Gestational Trophoblastic Disease ( GTD) a rare gyn cancer. I viewed on-demand the day after the presentation. 


Oral Abstract Session

Cervical Cancer - Keynote 826

 

 Ovarian cancer

 Ofranergene obadenove + weekly taxol

GOG 3025 -durvalumab + olaparib + bevacizumab

Luveltamab tazevibulin (STRO-002)


Endometrial Cancer 

 

Did I miss any important gyn studies? Please note them in the comment box. Thanks

Check back tomorrow for highlights from Day 3. 


Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , , , , , ,

Sunday, April 2, 2023

SGO Annual Mtg 2023 Highlights: Endometrial Cancer

The Late Breaking Abstracts session at the SGO Annual meeting included two important endometrial cancer studies using immune checkpoint inhibitors.

Dr Eskander presented Pembrolizumab versus Placebo in Addition to Carboplatin and Paclitaxel for Measurable Stage 3 or 4a, Stage 4b or recurrent Endometrial Cancer : Phase 3 NRG GYO18 Study (Keynote 868)

Pembrolizumab is an immune checkpoint inhibitor that binds to the protein PD-1.  Endometrial cancer patients who were stage III, IVa , IVB or recurrent endometrial cancer enrolled in the trial. They were given carboplatin / paclitaxel ( Standard of care) with pembrolizumab, a PD1 inhibitor or placebo followed by maintenance with pembrolizumab. Patients were separated into two cohorts according to whether they had mismatch repair–deficient (dMMR) or mismatch repair–proficient (pMMR) disease. The interim efficacy analysis showed in the pMMR cohort, median progression-free survival was 13.1 months with pembrolizumab and 8.7 months with placebo. 

The study was released minutes after the presentation Sunday afternoon in the NEJM.  https://www.nejm.org/doi/full/10.1056/NEJMoa2302312  Additional information may be found here.


Page 1 of "Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer" by Eskander et al.

Dr Mirza presented Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. (Ruby trial)

Dostarlimab, an immune checkpoint inhibitor to anti-programmed cell death receptor-1 (PD-1) was used in this Phase 3 trial. Women  with stage III, IV or recurrent endometrial cancer were give dostarlimab with carboplatin/ paclitaxel and then maintenance dostarlimab every 6 weeks for up to 3 years. In the dMMR–MSI-H ( mismatch repair–deficient, microsatellite instability–high) population, estimated progression-free survival at 24 months was 61.4%  versus 15.7% in the placebo group. Overall survival at 24 months was 71.3% with dostarlimab and 56.0% with placebo.   

This study was also published online in the NEJM shortly after the presentation. nej.md/40lFbBN
Additional information may be read here. 

Page 1 of "Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer" by Mirza et al.

This tweet sums up the two studies

Comments that I heard from various gynecologic oncologists after the session was that these two studies will impact endometrial cancer patient care in the near future.

 More SGO news to come!

 

Dee

Every day is a blessing!

Posted by at No comments:
Labels: , , , , , , ,

Tuesday, June 14, 2022

News from #ASCO22 Part 5 - Case Studies of Endometrial Cancer

This session was a case based discussion titled Controversies and Considerations in Adjuvant Advanced Endoemterial Cancer. 

Cases were presented and questions asked of the panel which included a patient advocate, @AdrienneEcana.

Tomorrow catch my last post from ASCO. It included varied Tweets of studies from the meeting that were not necessarily a part of the sessions I viewed.

 

Dee

Every Day is a Blessing! 

Posted by at 2 comments:
Labels: , , ,

Wednesday, March 30, 2022

SGO 2022 Annual Meeting Endometrial Cancer

Here are a few studies on endometrial cancer. Be sure to check my Disparities and Equity research post for those studies related to endometrial cancer. 

Phase 2, Two-Stage Study of Letrozole and Abemaciclib in Estrogen Receptor (ER) Positive Recurrent or Persistent Endometrial Cancer – Konstantinopoulos


 

 


EGFL6 is an Important Growth Factor Involved in Endometrial Cancer Tumorigenesis – A. Garrett

 


 

 

SIENDO/ENGOT-EN5/GOG-3055: A Randomized Phase 3 trial of Maintenance Selinexor Versus Placebo after Combination Platinum-Based Chemotherapy in Advanced or Recurrent Endometrial Cancer –  Vergote 


Ipatasertib, an Oral AKT Inhibitor, in Combination with Bevacizumab Exhibits Anti-Tumorigenic Effects in Pre-clinical Studies for Endometrioid Endometrial Cancer: Endometrial Cancer Molecularly Targeted Therapy Consortium –  M. Newton

 



In Vivo and In Vitro Efficacy of Enhertu in Uterine Serous Carcinoma – Speaker: L. Mutlu


 
Genomic Alterations, Molecularly Targeted Therapy and Race: Real World Data from the Endometrial Cancer Molecularly Targeted Therapy Consortium – A. Alvarez-Secord

 




 
 
 
Thanks for taking the time to read these SGO meeting posts. 
 
Dee
Every Day is a Blessing! 
 

Posted by at No comments:
Labels: , , , ,

Tuesday, June 8, 2021

ASCO 2021 Oral Abstract Session - GYN Cancers

I'll begin my coverage of the #ASCO21 Annual  meeting I have been attending virtually with comments and tweets from the Monday June 7th Gyneocologic Cancer Oral Abstract session. 


 

Not all the studies report were "blockbuster", not all provided results the researchers expected but in each and every one of them we - researchers, clinicians and patients learned something. 

 Here is my tweet summary:  

OVARIAN CANCER

PDL1 inhibitor / Neoadjuvant chemo plus Bevacizumab

GEM vaccine  (Gemogenovatucel)

Bevacizumab 15 months vs 30 months 

Agent given to highlight tumors with overexpression of folate receptor Alpha during surgery

Mirvetuximab plus Bev for recurrent OC

Adavosertib w and w/out Olaparib

Endometrial Cancer 

Intensive Follow-up after endometrial cancer treatment

mTOR inhibitor and Anastrozole 

Pertuzumab and Trastuzumab in uterine cancer patients with ERBB2/ERBB3 

 

Over the next few days I'll be sharing tweets from the disparity, plenary ( cervical cancer study)  and poster sessions. Stay tuned. 


Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , ,

Wednesday, March 24, 2021

2021 SGO Virtual Meeting Sunday March 21, 2021

I am happy to share with you Tweets that cover the work presented during the last full day session of SGO was on Sunday, March 21, 2021.

One session, Time to Return to the Drawing Board, reported clinical trial results that did not meet their aims. Understanding where a drug or treatment may have failed to provide the results expected is as important as those trials that meet aims.

 Atezolizumab

Falretuzumab

 

Durvalumab and Trememlimumab

Additional sessions of interest.

Barriers to Quality of Care - Poster 

Uterine lavage and early detection

Post operative opiods use model 

Neuropathy and genetic variants 

Gross resection and OS / NACT

Vulvar Cancer Studies 

Endometrial cancer 

Cediranib and Olaparib NRG GY012

IUD

 Enzalutamide


Here are some articles from various sources that go more into depth about studies discussed at the meeting. 

Medscape article on hormone IUD and endometrial cancer https://www.medpagetoday.com/meetingcoverage/sgo/91740

Vulvar cancer patients with sentinel node micrometastases, radiation therapy (RT) to the groin after local excision led to extremely low rates of recurrence, a phase II trial suggested https://www.medpagetoday.com/meetingcoverage/sgo/86603 

ABV-500 small molecule in OC https://www.medpagetoday.com/meetingcoverage/sgo/91739

 

Thank you so Eisai for supporting patient advocates at the annual meeting . 

Thank you SGO leadership for making us feel welcome and for all the gyn oncs who answered our questions.  

Dee

Every Day is a Blessing!

Posted by at No comments:
Labels: , , , , , , , , , , , ,
Subscribe to: Posts (Atom)